Literature DB >> 17289547

Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32).

P Conti1, P Youinou, T C Theoharides.   

Abstract

Interleukins (IL) and other cytokines display a number of overlapping abilities to stimulate cells of various lineages and differentiation stages. Most notably, IL-1, tumor necrosis factor (TNF)-alpha, IL-6, IL-15, IL-17, IL-18, IL-21, IL-25, IL-25, IL-31 and IL-32 contribute in concert to pathophysiological events. These include cell death, inflammation, allergy and autoimmunity. Up-regulation of either T helper (TH)1 or TH2 cells is pathogenic, and these subsets downregulate each other. The expression of chemokines/cytokines by endothelial cells is also crucial to autoimmunity by trafficking inflammatory T cells into the central-nervous system. IL-32 (previously termed NK transcript 4), is the newest inflammatory cytokine produced by mitogen-activated lymphocytes, interferon-gamma activated epithelial cells and IL-12, IL-18 and IL-32-activated NK cells. This induces TNF-alpha, IL-1beta, IL-6 and 2 C-X-C chemokine family members involved in several autoimmune diseases. In addition, IL-32 activates arachidonic acid metabolism in peripheral blood mononuclear cells by stimulating the release of prostaglandins. Discovery of this supplementary inflammatory cytokine further complicates the network of inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17289547     DOI: 10.1016/j.autrev.2006.08.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

1.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

2.  Elevated serum level of interleukin-32α in the patients with myasthenia gravis.

Authors:  Sang-Jun Na; Seon-Hwa So; Kee Ook Lee; Young-Chul Choi
Journal:  J Neurol       Date:  2011-04-13       Impact factor: 4.849

Review 3.  Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.

Authors:  Pio Conti; Francesco Carinci; Gianfranco Lessiani; Enrico Spinas; Spyridon K Kritas; Gianpaolo Ronconi; Alessandro Caraffa; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

4.  IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models.

Authors:  Young-Eun Park; Geun-Tae Kim; Seung-Geun Lee; Seong-Hu Park; Seung-Hoon Baek; Sung-Il Kim; Ju-In Kim; Hua-Shu Jin
Journal:  Rheumatol Int       Date:  2012-04-19       Impact factor: 2.631

5.  IL-32 expression is an independent prognostic marker for gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Yoshiaki Kita; Ken Sasaki; Hiroshi Okumura; Hiroshi Kurahara; Yuko Kijima; Aya Harada; Shinichi Ueno; Shoji Natsugoe
Journal:  Med Oncol       Date:  2013-03-12       Impact factor: 3.064

6.  Whither autoimmunity: the lessons of anti-CCP and B cell depletion.

Authors:  Yehuda Shoenfeld; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

7.  Differential effect of IL-1β and TNFα on the production of IL-6, IL-8 and PGE2 in fibroblast-like synoviocytes and THP-1 macrophages.

Authors:  Hyun Mi Choi; Da Hee Oh; Jun Soo Bang; Hyung-In Yang; Myung Chul Yoo; Kyoung Soo Kim
Journal:  Rheumatol Int       Date:  2009-08-21       Impact factor: 2.631

8.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

Review 9.  Pulmonary eosinophilia.

Authors:  Uriel Katz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

10.  Increased plasma interleukin-32 expression in patients with neuromyelitis optica.

Authors:  Honghao Wang; Kai Wang; Conghui Wang; Fangcheng Xu; Wei Qiu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-11-21       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.